Health Boards
I am re-starting this thread from the old forum, since this is my current psoriasis treatment.
What is Fumaderm?
Fumaderm® (fumaric acid esters) tablets are licensed in Germany for the treatment of adults with moderate to severe plaque psoriasis for whom topical therapy is ineffective.
It is beneficial in patients with moderate to severe psoriasis, particularly chronic plaque, guttate or pustular disease; at least 50% of patients treated with Fumaderm® will have a reduction of about 70% or more in Psoriasis Area and Severity Index (PASI) score after 16 weeks of treatment.
Data from controlled and observational studies show Fumaderm® is effective as a first-line systemic agent in patients not responding to topical therapy, as an alternative to other systemic agents that are ineffective or not tolerated.
Adverse effects, including diarrhoea, abdominal pain and facial flushing, are common at the start of treatment with Fumaderm® and lead to discontinuation and/or non-compliance in 30 to 40% of patients.
Reversible leucopenia, lymphopenia and transient eosinophilia are frequently observed. Observational studies following patients for up to 14 years do not indicate that Fumaderm® is associated with serious or permanent adverse effects. Increases in serum creatinine and liver function tests occur rarely and resolve with continued treatment or on dose reduction.
EDIT By Fred: Jim has also made a thread from the prescribing leaflet that may be of interest. Fumaderm leaflet
Posts from this thread have been split to: [split] Fumaderm
What is Fumaderm?
Fumaderm® (fumaric acid esters) tablets are licensed in Germany for the treatment of adults with moderate to severe plaque psoriasis for whom topical therapy is ineffective.
It is beneficial in patients with moderate to severe psoriasis, particularly chronic plaque, guttate or pustular disease; at least 50% of patients treated with Fumaderm® will have a reduction of about 70% or more in Psoriasis Area and Severity Index (PASI) score after 16 weeks of treatment.
Data from controlled and observational studies show Fumaderm® is effective as a first-line systemic agent in patients not responding to topical therapy, as an alternative to other systemic agents that are ineffective or not tolerated.
Adverse effects, including diarrhoea, abdominal pain and facial flushing, are common at the start of treatment with Fumaderm® and lead to discontinuation and/or non-compliance in 30 to 40% of patients.
Reversible leucopenia, lymphopenia and transient eosinophilia are frequently observed. Observational studies following patients for up to 14 years do not indicate that Fumaderm® is associated with serious or permanent adverse effects. Increases in serum creatinine and liver function tests occur rarely and resolve with continued treatment or on dose reduction.
EDIT By Fred: Jim has also made a thread from the prescribing leaflet that may be of interest. Fumaderm leaflet
Posts from this thread have been split to: [split] Fumaderm